for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vifor Pharma AG

VIFN.S

Latest Trade

181.50CHF

Change

-0.85(-0.47%)

Volume

194,802

Today's Range

181.50

 - 

184.35

52 Week Range

122.30

 - 

186.30

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
182.35
Open
183.75
Volume
194,802
3M AVG Volume
3.37
Today's High
184.35
Today's Low
181.50
52 Week High
186.30
52 Week Low
122.30
Shares Out (MIL)
64.84
Market Cap (MIL)
11,797.50
Forward P/E
--
Dividend (Yield %)
1.10

Next Event

Full Year 2019 Vifor Pharma AG Earnings Release

Latest Developments

More

ChemoCentryx And VFMCRP Announce Positive Topline Data From Pivotal Phase III ADVOCATE Trial

Vifor Pharma Appoints Lee Heeson As President International And Member Of Executive Committee

Vifor Pharma And Evotec Form Joint Venture For Early Development In Nephrology

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vifor Pharma AG

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Contact Info

Rechenstrasse 37

+41.58.8528111

http://www.viforpharma.com

Executive Leadership

Etienne Jornod

Executive Chairman of the Board of Directors

Stefan Schulze

President of the Executive Committee, Chief Operating Officer

Romeo Cerutti

Deputy Chairman of the Board

Colin Bond

Chief Financial Officer, Member of the Executive Committee

Patrick Treanor

President of Relypsa

Key Stats

2.54 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

4.3K

2017

1.3K

2018

1.6K

2019(E)

1.9K
EPS (CHF)

2016

3.756

2017

0.520

2018

2.340

2019(E)

3.570
Price To Earnings (TTM)
118.81
Price To Sales (TTM)
6.74
Price To Book (MRQ)
3.94
Price To Cash Flow (TTM)
29.07
Total Debt To Equity (MRQ)
22.41
LT Debt To Equity (MRQ)
18.56
Return on Investment (TTM)
6.11
Return on Equity (TTM)
4.93

Latest News

Latest News

BRIEF-Vifor Pharma Appoints Lee Heeson As President International And Member Of Executive Committee

* APPOINTS LEE HEESON AS PRESIDENT INTERNATIONAL AND MEMBER OF EXECUTIVE COMMITTEE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Vifor Pharma And Evotec Form Joint Venture For Early Development In Nephrology

* VIFOR PHARMA AND EVOTEC FORM JOINT VENTURE FOR EARLY DEVELOPMENT IN NEPHROLOGY

BRIEF-Vifor Pharma Enters Into Commercial Collaboration In US With Janssen

* AGREEMENT TO JOINTLY COMMERCIALISE NEW DIABETIC KIDNEY DISEASE (DKD) INDICATION FOR INVOKANA(®) (CANAGLIFLOZIN) IN US Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Vifor Pharma Appoints New Chief Medical Officer

* VIFOR PHARMA APPOINTS NEW CHIEF MEDICAL OFFICER AND ANNOUNCES CHANGES TO EXECUTIVE COMMITTEE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vifor Pharma H1 EBITDA Of CHF 254.6 Million, Up 32.6%

* VIFOR PHARMA GROUP REPORTS STRONG H1 2019 RESULTS AND RAISES FULL-YEAR GUIDANCE

BRIEF-Vifor Pharma'S Phase-II Amber Study Meets Primary Endpoint

* VIFOR PHARMA AG - VELTASSA WAS SHOWN TO ENABLE PERSISTENT USE OF SPIRONOLACTONE BY CONTROLLING BLOOD POTASSIUM LEVELS

BRIEF-Vifor Pharma FY EBITDA Of CHF 391.5 Million, Up 39.7 Pct

* FY NET SALES OF CHF 1,584.6 MILLION, UP 22.7%; EBITDA OF CHF 391.5 MILLION, UP 39.7%

BRIEF-Vifor Pharma and Chemocentryx Withdraw Marketing Authorisation Application For Avacopan

* CHEMOCENTRYX ANNOUNCES WITHDRAWAL OF PHASE II-BASED CONDITIONAL MARKETING AUTHORISATION (CMA) APPLICATION FOR ANCA-ASSOCIATED VASCULITIS IN EUROPE, PHASE III ADVOCATE TRIAL DATA RELEASE PLANNED FOR Q4 2019

BRIEF-Vifor Pharma Receives Positive Phase-I Trial Results For Oral Ferroportin Inhibitor

* VIFOR PHARMA RECEIVES POSITIVE PHASE-I TRIAL RESULTS FOR ORAL FERROPORTIN INHIBITOR

BRIEF-Vifor Pharma: Patrick Treanor Appointed President Of Relypsa

* PATRICK TREANOR APPOINTED PRESIDENT OF RELYPSA AND MEMBER OF THE EXECUTIVE COMMITTEE OF VIFOR PHARMA GROUP Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vifor Pharma: Pivotal Trial Confirms Long-Term Safety And Efficacy Of IV Iron Dosing Strategy

* PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vifor Pharma Announces Changes In Management

* BARBARA ANGEHRN JOINS VIFOR PHARMA AS CHIEF BUSINESS OFFICER

BRIEF-Vifor Pharma Increases Equity Investment In ChemoCentryx

* INCREASES EQUITY STAKE IN CHEMOCENTRYX FROM 6.6% TO 21.2% Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vifor Pharma Issues Inaugural CHF 465 Million Bond

* BOND CARRIES A 0.75% FIXED COUPON WITH A TENOR OF 4 YEARS, MATURING ON 13 SEPTEMBER 2022 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vifor Pharma H1 EBITDA Up 44.5 Pct At CHF 192.0 Million

* VIFOR PHARMA GROUP REPORTS STRONG H1 2018 RESULTS, RAISES FULL-YEAR GUIDANCE

BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus

* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

AstraZeneca potassium drug finally approved, threatening Vifor

The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

BRIEF-Vifor Pharma Says US FDA Approves Use Of Veltassa With Or Without Food

* VIFOR PHARMA AG - UPDATED LABEL MAY ALLOW FOR INCREASED DOSING FLEXIBILITY FOR PATIENTS WITH HYPERKALAEMIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vifor Pharma FY EBITDA Down At CHF 280.4 Mln

* FY SIGNIFICANT REVENUE GROWTH, WITH NET SALES OF CHF 1,342.1 MILLION, UP 15.2% ON A CONSTANT CURRENCY BASIS

BRIEF-Vifor Pharma: Ferroportin Inhibitor Enters Phase-I Clinical Trial

* FIRST RESULTS FROM THE STUDY ARE EXPECTED IN THE SECOND HALF OF 2018 Source text - http://bit.ly/2FSyjCD Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up